Analisi delle prescrizioni farmaceutiche e dei costi del trattamento del carcinoma prostatico nell’ULSS 9 di Treviso

Abstract

Objective In Italy, the standard curative treatment for prostate carcinoma with metastases is the androgen suppression therapy (AST). Recently, intermittent AST has been introduced for the treatment of androgen-responsive patients aged > 75 years in order to reduce the toxicity and cost of treatment, as well as to delay tumor progression. The purpose of this study was to perform a cost-analysis of standard AST, intermittent AST or bilateral surgical castration.